UBS Group Lowers Alexion Pharmaceuticals (ALXN) to Outperform

Alexion Pharmaceuticals (NASDAQ:ALXN) was downgraded by equities research analysts at UBS Group from a “strong-buy” rating to an “outperform” rating in a report issued on Thursday, The Fly reports.

Several other analysts have also commented on ALXN. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 27th. Leerink Swann restated a “buy” rating and set a $182.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, September 25th. BMO Capital Markets restated an “outperform” rating and set a $173.00 price target (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. SunTrust Banks restated a “buy” rating and set a $180.00 price target (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Robert W. Baird upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price target on the stock in a research report on Monday, December 18th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $155.70.

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) opened at $124.95 on Thursday. The firm has a market cap of $27,713.96, a price-to-earnings ratio of 55.78, a PEG ratio of 1.04 and a beta of 1.18. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.12. The firm had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.23 earnings per share. research analysts forecast that Alexion Pharmaceuticals will post 4.82 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in ALXN. Beacon Capital Management purchased a new stake in shares of Alexion Pharmaceuticals during the 4th quarter worth approximately $0. Advantage Investment Management LLC purchased a new stake in shares of Alexion Pharmaceuticals during the 4th quarter worth approximately $101,000. Guardian Life Insurance Co. of America lifted its position in shares of Alexion Pharmaceuticals by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in Alexion Pharmaceuticals in the 1st quarter valued at $111,000. Finally, Fiduciary Trust Co. purchased a new stake in Alexion Pharmaceuticals in the 2nd quarter valued at $111,000. 94.26% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/04/ubs-group-lowers-alexion-pharmaceuticals-alxn-to-outperform.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

The Fly

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply